Increased B-type natriuretic peptide (BNP) level is a strong predictor for cardiac dysfunction in intensive care unit patients

Anaesthesia and Intensive Care

Volumn 31, Issue 1, 2003, Pages 21-27

  McLean, A S ^a   Tang, B ^a   Nalos, M ^a   Huang, S J ^a   Stewart, D E ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Brain natriuretic peptide: cardiac dysfunction; Intensive care unit

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; FEMALE; HEART DISEASE; HEART FAILURE; HOSPITAL ADMISSION; HOSPITAL PATIENT; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; PATIENT CARE; PEPTIDE ANALYSIS; PREDICTION; SCREENING TEST; SENSITIVITY AND SPECIFICITY;

EID: 0037328683     PISSN: 0310057X     EISSN: None     Source Type: Journal    
DOI: 10.1177/0310057x0303100104     Document Type: Article

References (30)

1. Sudoh T, Minamino N, Kangawa K, Matsuo H. A new natriuretic peptide in human brain. Nature 1988; 332:78-81.
2. Morita H, Nishada Y, Motochigawa H et al. Effects of brain natriuretic peptide on renal nerve activity in conscious rabbit. Am J Physiol 1989; 256:R792-R796.
3. Nishida Y, Morita H, Minamino N et al. Effects of brain natriuretic peptide on hemodynamics and renal functions in dogs. Jpn J Physiol 1990; 40:531-540.
4. Edwards BS, Zimmerman RS, Schwab TR et al. Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. Cir Res 1988; 62:191-195.
5. Mukoyama M, Nakao K, Hosoda K et al. Brain natriuretic peptide as a novel cardiac hormone in humans: evidence for an exquisite dual natriuretic peptide system, atrial natriuretic peptide and brain natriuretic peptide. J Clin Invest 1991; 87:1402-1412.
6. Nagagawa O, Ogawa Y, Itoh H et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J Clin Invest 1995; 96:1280-1287.
7. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet 1998; 35:3-4.
8. Maeda K, Tsutamoto T, Wada A et al. Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction. Am Heart J 1998; 135:825-832.
9. Dao Q, Krishnaswamy P, Kazanegra R et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J Am Coll Card 2001; 37:379-385.
10. Maisel AS, Koon, J, Krisnaswamy P et al. Utility of B-natriuretic peptide as a rapid, point-of-care test for screening patients undergoing echocardiography to determine left ventricular dysfunction. Am Hear J 2001; 141:367-374.
11. Maisel AS, Krishnaswamy P, Nowak RM et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med 2002; 347:161-167.
12. Cabanes L, Richaud-Thiriez B, Fula Y et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest 2001; 120:2047-2050.
13. Stevenson LV. The limited availability of physical signs for estimating hemodynamics in chronic heart failure. JAMA 1989; 261:884-888.
14. Deveraux RB, Liebson PR, Horan MJ. Recommendations concerning use of echocardiography in hypertension and general population research. Hypertension 1987; 9:97-104.
15. Pfeifer MA, Braunwald E, Moyle LA et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: the SAVE Investigation. N Engl J Med 1992; 327:669-677.
16. Fischer Y, Fitzmaier K, Stiegler H et al. Evaluation of a new, rapid bedside test for quantitative determination of B-type natriuretic peptide (BNP). Clin Chem 2001; 47:591-594.
17. McLean A. Critical care echocardiography. Crit Care Shock 2001; 2:61-69.
18. Schiller N, Shah P, Crawford M et al. Recommendations for quantification of the left ventricle by two-dimensional echocardiography. Am Soc Echocardiogr 1989; 2:358-367.
19. Hammarstrom E, Wranne B, Pinto FJ et al. Tricuspid annular motion. J Am Soc Echo 1991;4:131-139.
20. Wang CH, Cheng WJ, Meng HC et al. Relationship between dobutamine echocardiography and the elevation of cardiac troponin I in patients with acute coronary syndromes. Echocardiography 2001; 18:573-579.
21. Engel G, Rockson SG. Feasibility and reliability of rapid diagnosis of myocardial infarction. Am J Med Sci 2001; 322:339-344.
22. Benoit MO. Paris M. Silleran J, et al. Cardiac troponin I: Its contribution to the diagnosis of perioperative myocardial infarction and various complications of cardiac surgery. Crit Care Med 2001; 29:2023-2024
23. McDonagh TA, Robb SD, Murdoch DR et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998;351:9-13.
24. Bettencourt P, Ferreira A, Dias P et al. Evaluation of brain natriuretic peptide in the diagnosis of heart failure. Cardiology 2000;93:19-25.
25. Lubien E, DeMaria A, krishnaswamy P et al. Utility of B-Natriuretic peptide in detecting diastolic dysfunction. Circulation 2002; 105:595-601.
26. Clerico A, Levasi G, Chicca M, et al. Circulating levels cardiac natriuretic peptides (ANP and BNP) measured by highly sensitive and specific immunoradiometric assays in normal subjects and in patients with different degrees of heart failure. J Endocrine Invest 1998; 21:170-179.
27. Su X, Brower G, Janicki JS et al. Differential expression of natriuretic peptides and their receptors in volume overload cardiac hypertrophy in the rat. J Mol Cell Cardiol 1999; 31:1927-1936.
28. Adachi S, Ito H, Ohta Y et al. Distribution of mRNAs for natriuretic peptides in RV hypertrophy after pulmonary arterial banding. Am J Physiol 1995; 268(1 Pt 2):H162-H169.
29. Miyatake K, Kangawa K. Plasma brain natriuretic peptide as a prognostic indicator in patients with primary pulmonary hypertension. Circulation 2000; 102:865-870.
30. McDonagh TA, Morrison CE, Lawrence A et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet 1997; 350:829-833.